ArticlePharmaceutical development and technology
Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells.
Article in Pharmaceutical development and technology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Poly(galactaramidoamine) (PGAA) is a cationic co-polymer of dimethyl-meso-galactarate and pentaethylenehexamine. PGAA electrostatically complexes with plasmid DNA (pDNA) to form nano-sized particles. In this study, we show that PGAA-pDNA polyplexes generate high transfection efficiencies in human embryonic kidney (HEK293) and murine macrophage-like (RAW264.7) cell lines. PGAA-pDNA mediated transfection is a function of the amine:phosphate (N/P) ratio at which the polyplexes are prepared. The maximum expression of luciferase was obtained using polyplexes prepared at an N/P ratio of 40. Polyplexes prepared at increasing N/P ratios did not significantly increase in size but did result in decreasing luciferase expression. Cellular toxicity increased as the N/P ratios at which the polyplexes were prepared increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.